Floxuridine (FUDR)

別名: NSC 27640, Deoxyfluorouridine 中文名稱：氟尿苷

目錄號：S1299 Purity: 99.99%

Floxuridine (FUDR)是一種前體藥物，在體內(nèi)可迅速分解為5-fluorouracil。Floxuridine 可用于治療各種癌癥，特別是轉(zhuǎn)移到肝臟的癌癥。Floxuridine 可抑制 Poly(ADP-Ribose) polymerase、誘導(dǎo)DNA損傷和凋亡。Floxuridine 對HSV和CMV具有抗病毒作用。

Floxuridine (FUDR) Chemical Structure

CAS: 50-91-9

規(guī)格	價(jià)格	庫存
10mM (1mL in DMSO)	1270	現(xiàn)貨
50mg	782.46	現(xiàn)貨
200mg	2439.19	現(xiàn)貨
更大包裝有超大折扣
400-668-6834 [email protected]

產(chǎn)品質(zhì)控

批次：純度： 99.99%

99.99

Floxuridine (FUDR)相關(guān)產(chǎn)品

相關(guān)靶點(diǎn)	tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase	點(diǎn)擊展開
相關(guān)產(chǎn)品	CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 Triapine (3-AP) Carmofur BMH-21 B02 YK-4-279 Bergapten Azaguanine-8 Halofuginone Adenine HCl Tegafur (FT-207) Mizoribine Cyclocytidine HCl Thymidine Nedaplatin APX-3330 Flupirtine maleate Pritelivir (BAY 57-1293) 6-Thio-dG JH-RE-06 TK216 CRT0044876 Adenine Tubercidin Amenamevir Madrasin ML216 PFM01 BC-LI-0186	點(diǎn)擊展開
相關(guān)化合物庫	FDA藥物庫天然產(chǎn)物庫凋亡分子化合物庫 DNA損傷/ DNA修復(fù)化合物庫細(xì)胞周期化合物庫	點(diǎn)擊展開

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

細(xì)胞系	實(shí)驗(yàn)類型	給藥濃度	孵育時(shí)間	活性描述
Colo-357 cells	Function assay	100 μM	15 mins	Activity at MRP5 in human Colo-357 cells assessed as 5-FdUMP accumulation at 100 uM after 15 mins
L1210 mouse leukemia cells	Growth inhibition assay		24 h	Growth inhibition in L1210 mouse leukemia cells after 24 h treatment, IC50=0.0041 μM
L1210 mouse leukemia cells	Growth inhibition assay		48 h	Growth inhibition in L1210 mouse leukemia cells after 48 hr treatment, IC50=0.00064 μM
L1210 mouse leukemia cells	Function assay		2 h	Thymidylate synthase inhibition in L1210 mouse leukemia cells after 2 hr treatment, IC50=0.0079 μM
LM cells	Function assay		2 h	Thymidylate synthase inhibition in thymidine kinase deficient LM cells after 2 hr treatment, IC50=5.4 μM
L1210 cells	Growth inhibition assay		72 h	Cytostatic activity against mouse L1210 cells ATCC CCL219 assessed as growth reduction after 72 hrs, IC50=0.012 μM
HL60 cells	Growth inhibition assay		72 h	Cytostatic activity against human HL60 cells ATCC CCL 240 assessed as growth reduction after 72 hrs, IC50=0.012 μM
CCRF-CEM cells	Growth inhibition assay		72 h	Cytostatic activity against human CCRF-CEM cells ATCC CCL 119 assessed as growth reduction after 72 hrs, IC50=0.017 μM
L1210 cells	Growth inhibition assay		72 h	Cytostatic activity in mouse L1210 cells assessed as inhibition of cell growth after 72 hrs, IC50=0.012 μM
HL60 cells	Growth inhibition assay		72 h	Cytostatic activity in human HL60 cells assessed as inhibition of cell growth after 72 hrs, IC50=0.012 μM
CCRF-CEM cells	Growth inhibition assay		72 h	Cytostatic activity in human CCRF-CEM cells assessed as inhibition of cell growth after 72 hrs, IC50=0.017 μM
CCRF-CEM cells	Function assay		48 h	Anticancer activity against human CCRF-CEM cells after 48 hrs by sulforhodamine B assay, GI50=0.00631 μM
K562 cells	Function assay		48 h	Anticancer activity against human K562 cells after 48 hrs by sulforhodamine B assay, GI50=0.79433 μM
MOLT4 cells	Function assay		48 h	Anticancer activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay, GI50=0.03981 μM
RPMI8266 cells	Function assay		48 h	Anticancer activity against human RPMI8266 cells after 48 hrs by sulforhodamine B assay, GI50=0.79433 μM
human SR cells	Function assay		48 h	Anticancer activity against human SR cells after 48 hrs by sulforhodamine B assay, GI50=0.01259 μM
A549 cells	Function assay		48 h	Anticancer activity against human A549 cells after 48 hrs by sulforhodamine B assay, GI50=0.01259 μM
EKVX cells	Function assay		48 h	Anticancer activity against human EKVX cells after 48 hrs by sulforhodamine B assay, GI50=10 μM
HOP62 cells	Function assay		48 h	Anticancer activity against human HOP62 cells after 48 hrs by sulforhodamine B assay, GI50=0.02512 μM
HOP92 cells	Function assay		48 h	Anticancer activity against human HOP92 cells after 48 hrs by sulforhodamine B assay, GI50=0.79433 μM
NCI-H226 cells	Function assay		48 h	Anticancer activity against human NCI-H226 cells after 48 hrs by sulforhodamine B assay
NCI-H23	Function assay		48 h	Anticancer activity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM
NCI-H322	Function assay		48 h	Anticancer activity against human NCI-H322M cells after 48 hrs by sulforhodamine B assay, GI50=0.50119 μM
NCI-H460	Function assay		48 h	Anticancer activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay, GI50=0.50119 μM
NCI-H522	Function assay		48 h	Anticancer activity against human NCI-H522 cells after 48 hrs by sulforhodamine B assay, GI50=0.002 μM
COLO205 cells	Function assay		48 h	Anticancer activity against human COLO205 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM
HCC2998 cells	Function assay		48 h	Anticancer activity against human HCC2998 cells after 48 hrs by sulforhodamine B assay, GI50=1.58489 μM
HCT116 cells	Function assay		48 h	Anticancer activity against human HCT116 cells after 48 hrs by sulforhodamine B assay, GI50=0.001 μM
HCT15 cells	Function assay		48 h	Anticancer activity against human HCT15 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM
HT-29 cells	Function assay		48 h	Anticancer activity against human HT-29 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM
KM12 cells	Function assay		48 h	Anticancer activity against human KM12 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM
SW620 cells	Function assay		48 h	Anticancer activity against human SW620 cells after 48 hrs by sulforhodamine B assay, GI50=6.30957 μM
SF268 cells	Function assay		48 h	Anticancer activity against human SF268 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM
SF295 cells	Function assay		48 h	Anticancer activity against human SF295 cells after 48 hrs by sulforhodamine B assay, GI50=0.01259 μM
SF539 cells	Function assay		48 h	Anticancer activity against human SF539 cells after 48 hrs by sulforhodamine B assay, GI50=0.03981 μM
SNB19 cells	Function assay		48 h	Anticancer activity against human SNB19 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM
SNB75 cells	Function assay		48 h	Anticancer activity against human SNB75 cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM
U251 cells	Function assay		48 h	Anticancer activity against human U251 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM
LOXIMVI cells	Function assay		48 h	Anticancer activity against human LOXIMVI cells after 48 hrs by sulforhodamine B assay, GI50=0.02512 μM
MALME-3M cells	Function assay		48 h	Anticancer activity against human MALME-3M cells after 48 hrs by sulforhodamine B assay, GI50=7.94328 μM
M14 cells	Function assay		48 h	Anticancer activity against human M14 cells after 48 hrs by sulforhodamine B assay, GI50=0.15849 μM
SK-MEL-2 cells	Function assay		48 h	Anticancer activity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM
SK-MEL-28 cells	Function assay		48 h	Anticancer activity against human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM
SK-MEL-5 cells	Function assay		48 h	Anticancer activity against human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM
UACC257 cells	Function assay		48 h	Anticancer activity against human UACC257 cells after 48 hrs by sulforhodamine B assay, GI50=3.16228 μM
UACC62 cells	Function assay		48 h	Anticancer activity against human UACC62 cells after 48 hrs by sulforhodamine B assay, GI50=0.03981 μM
IGROV1 cells	Function assay		48 h	Anticancer activity against human IGROV1 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM
OVCAR-3 cells	Function assay		48 h	Anticancer activity against human OVCAR-3 cells after 48 hrs by sulforhodamine B assay, GI50=2.51189 μM
OVCAR4 cells	Function assay		48 h	Anticancer activity against human OVCAR4 cells after 48 hrs by sulforhodamine B assay, GI50=10 μM
OVCAR5 cells	Function assay		48 h	Anticancer activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay, GI50=6.30957 Μm
OVCAR8 cells	Function assay		48 h	Anticancer activity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM
SKOV3 cells	Function assay		48 h	Anticancer activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay, GI50=1.99526 μM
786-0 cells	Function assay		48 h	Anticancer activity against human 786-0 cells after 48 hrs by sulforhodamine B assay, GI50=0.1 μM
A498 cells	Function assay		48 h	Anticancer activity against human A498 cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM
ACHN cells	Function assay		48 h	Anticancer activity against human ACHN cells after 48 hrs by sulforhodamine B assay, GI50=0.03162 μM
Caki1 cells	Function assay		48 h	Anticancer activity against human Caki1 cells after 48 hrs by sulforhodamine B assay, GI50=0.03162 μM
SN12C cells	Function assay		48 h	Anticancer activity against human SN12C cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM
TK10 cells	Function assay		48 h	Anticancer activity against human TK10 cells after 48 hrs by sulforhodamine B assay, GI50=5.01187 μM
UO31 cells	Function assay		48 h	Anticancer activity against human UO31 cells after 48 hrs by sulforhodamine B assay, GI50=0.12589 μM
PC3 cells	Function assay		48 h	Anticancer activity against human PC3 cells after 48 hrs by sulforhodamine B assay, GI50=0.31623 μM
DU145 cells	Function assay		48 h	Anticancer activity against human DU145 cells after 48 hrs by sulforhodamine B assay, GI50=0.25119 μM
MCF7 cells	Function assay		48 h	Anticancer activity against human MCF7 cells after 48 hrs by sulforhodamine B assay, GI50=0.00631 μM
NCI/ADR-RES cells	Function assay		48 h	Anticancer activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM
MDA-MB-231 cells	Function assay		48 h	Anticancer activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay, GI50=3.98107 μM
Hs 578T cells	Function assay		48 h	Anticancer activity against human Hs 578T cells after 48 hrs by sulforhodamine B assay, GI50=3.98107 μM
MDA-MB-435 cells	Function assay		48 h	Anticancer activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay, GI50=3.16228 μM
MDA-N cells	Function assay		48 h	Anticancer activity against human MDA-N cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM
BT549 cells	Function assay		48 h	Anticancer activity against human BT549 cells after 48 hrs by sulforhodamine B assay, GI50=1 μM
T47D cells	Function assay		48 h	Anticancer activity against human T47D cells after 48 hrs by sulforhodamine B assay, GI50=1.25893 μM
HepG2 cells	Cytotoxicity assay		72 h	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, EC50=18.84 μM
A549 cells	Cytotoxicity assay		72 h	Cytotoxicity against human A549 cells after 72 hrs by MTT assay, EC50=9.74 μM
LAC cells	Cytotoxicity assay		72 h	Cytotoxicity against human LAC cells after 72 hrs by MTT assay, EC50=32.09 μM
HeLa cells	Cytotoxicity assay		72 h	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay, EC50=10.26 μM
FM3A cells	Function assay		2 days	Cytostatic activity against mouse FM3A cells after 2 days by coulter counting analysis, IC50=0.0094 μM
LLC cells	Cytotoxicity assay		24 h	Cytotoxicity against mouse LLC cells after 24 hrs by resazurin assay, IC50=14.2 μM
LLC cells	Cytotoxicity assay		72 h	Cytotoxicity against mouse LLC cells after 72 hrs by resazurin assay, IC50=2 μM
RAW264.7 cells	Cytotoxicity assay		72 h	Cytotoxicity against mouse RAW264.7 cells after 72 hrs by resazurin assay, IC50=30 μM
A549 cells	Cytotoxicity assay		72 h	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by WST-8 assay, IC50=0.047 μM
A2780 cells	Cytotoxicity assay		5 days	Cytotoxicity against human A2780 cells after 5 days by MTT assay, IC50=0.026 μM
LMTK cells	Cytotoxicity assay		5 days	Cytotoxicity against thymidine kinase-deficient mouse LMTK cells after 5 days by MTT assay, IC50=4.5 μM
A549 cells	Cytotoxicity assay		72 h	Cytotoxicity against human A549 cells after 72 hrs by microplate reader method, IC50=0.0124 μM
CEM cells	Function assay		72 h	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR, IC50=0.8 μM
Hela cells	Function assay		72 h	Cytostatic activity against human HeLa cells after 72 hrs by cell counting, IC50=0.05 μM
CEM/0 cells	Function assay		72 h	Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting, IC50=0.022 μM
L1210/0 cells	Function assay		48 h	Cytostatic activity against mouse L1210/0 cells after 48 hrs by cell counting, IC50=0.0009 μM
MCF7 cells	Cytotoxicity assay		72 h	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay, IC50=12.19 μM
HeLa cells	Cytotoxicity assay		72 h	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay, IC50=6.5 μM
HL60 cells	Proliferation assay		72 h	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.24 μM
SW707 cells	Proliferation assay		72 h	Antiproliferative activity against human SW707 cells assessed as growth inhibition after 72 hrs by SRB method, IC50=23.86 μM
LoVo cells	Proliferation assay		72 h	Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method, IC50=19.07 μM
BALB/3T3 cell	Proliferation assay		72 h	Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method, IC50=23.9 μM
HFF cells	Function assay		72 h	Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay, EC50=0.91 μM
RXF393 cells	Function assay		48 h	Anticancer activity against human RXF393 cells after 48 hrs by sulforhodamine B assay, GI50=3.98107 μM
HL-60(TB) cells	Function assay		48 h	Anticancer activity against human HL-60(TB) cells after 48 hrs by sulforhodamine B assay, GI50=0.19953 μM
L1210 cells	Function assay		15 mins	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 15 mins by liquid scintillation counting, IC50=0.0006 μM
KB cells	Cytotoxicity assay		72 h	Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50=8.69 μM
CCRF-CEM cell	Growth inhibition assay			Tested in vitro for the inhibition of cell growth of human T lymphoblastoid CCRF-CEM cell line (ATCC CCL 119), IC50=0.5 μM
CCRF-CEM	Growth inhibition assay			In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL), GI50=0.0006 μM
LNCaP cells	Cytotoxicity assay			Cytotoxic concentration in prostate specific antigen (PSA) producing human LNCaP cells, IC50=0.0692 μM
TSU cells	Cytotoxicity assay			Cytotoxic concentration in non prostate specific antigen (PSA) producing human TSU cells, IC50=0.058 μM
KBALB cell	Cytotoxicity assay			In vitro cell cytotoxicity against KBALB cell line (transformed fibroblast sarcoma cell line), CC50=6.00E-05 μM
KBALB-STK cell	Cytotoxicity assay			In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK, IC50=8.80E-05 μM
L5178Y cell	Growth inhibition assay			Comparative inhibition of L5178Y cell growth in vitro (concentration required for 50% inhibition), IC50=0.00076 μM
L5178Y cells	Function assay			Inhibitory concentration of compound was calculated on L5178Y cells by [14C]Leu incorporation, IC50=2 μM
HT1080 cells	Function assay			Cytostatic activity against human HT1080 cells by MTT assay, IC50=0.18 μM
MDA-MB-231 cells	Cytotoxicity assay			Cytotoxicity against human MDA-MB-231 cells overexpressing urokinase plasminogen activator, IC50=0.21 μM
human ACHN cells	Function assay			Anticancer activity against human ACHN cells by SRB assay, GI50=2.1 μM
PC3 cells	Function assay			Anticancer activity against human PC3 cells by SRB assay, GI50=4.97 μM
MDA-MB-231 cells	Function assay			Anticancer activity against human MDA-MB-231 cells by SRB assay, GI50=0.16 μM
HeLa cells	Function assay			Cytostatic activity against human HeLa cells in presence of 20 uM thymidine, IC50=8.5 μM
CCRFCEM cells	Function assay			Cytostatic activity against human CCRFCEM cells by MTT assay, IC50=0.29 μM
點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù)

生物活性

產(chǎn)品描述	Floxuridine (FUDR)是一種前體藥物，在體內(nèi)可迅速分解為5-fluorouracil。Floxuridine 可用于治療各種癌癥，特別是轉(zhuǎn)移到肝臟的癌癥。Floxuridine 可抑制 Poly(ADP-Ribose) polymerase、誘導(dǎo)DNA損傷和凋亡。Floxuridine 對HSV和CMV具有抗病毒作用。

體外研究(In Vitro)
體外研究活性	Floxuridine呈現(xiàn)對PEPT1比相應(yīng)的5'-O-單氨基酸酯前藥更高的親和力。^[1] Floxuridine和Leucovorin聯(lián)用導(dǎo)致人T淋巴細(xì)胞白血病細(xì)胞生長的協(xié)同抑制作用。^[2] Floxuridine顯著抑制[(3)H]-inosine和[(3)H]腺苷的的攝取（對照的60-70％），而它的氨基酸酯前體，包括纈氨酸，苯丙氨酸，Asp和賴氨酸酯，顯著下降抑制效力（對照的10-30％）。^[3] Floxuridine在36天抑制細(xì)胞增值超過對照細(xì)胞的50％，細(xì)胞數(shù)量和初始細(xì)胞密度相比增加了4倍。Floxuridine導(dǎo)致對體外培養(yǎng)的人眼球筋膜囊成纖維細(xì)胞增殖長時(shí)間延長。^[4] Floxuridine是一種理想的肝動(dòng)脈灌注（HAI）藥物，由于其半衰期短，陡峭的劑量反應(yīng)曲線，高總清除率和高肝提取。^[5]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試驗(yàn)信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT01042691	Completed	Unresectable Colorectal Liver Metastases	David Bartlett\|The Pittsburgh Foundation\|Sanofi\|University of Pittsburgh	May 2003	Phase 1
NCT00695201	Completed	Colon Cancer\|Rectal Cancer	Memorial Sloan Kettering Cancer Center\|University of Medicine and Dentistry of New Jersey\|Rutgers The State University of New Jersey\|Sanofi	August 2000	Phase 1

參考文獻(xiàn)
https://pubmed.ncbi.nlm.nih.gov/18652477/ https://pubmed.ncbi.nlm.nih.gov/2950995/ https://pubmed.ncbi.nlm.nih.gov/16462026/ https://pubmed.ncbi.nlm.nih.gov/1386726/ https://pubmed.ncbi.nlm.nih.gov/19383854/ + 展開

參考文獻(xiàn)

https://pubmed.ncbi.nlm.nih.gov/18652477/
https://pubmed.ncbi.nlm.nih.gov/2950995/
https://pubmed.ncbi.nlm.nih.gov/16462026/

https://pubmed.ncbi.nlm.nih.gov/1386726/
https://pubmed.ncbi.nlm.nih.gov/19383854/

+ 展開

化學(xué)信息&溶解度

分子量	246.19	分子式	C₉H₁₁FN₂O₅
CAS號	50-91-9	SDF	Download Floxuridine (FUDR) SDF
Smiles	C1C(C(OC1N2C=C(C(=O)NC2=O)F)CO)O
儲存條件(自收到貨起)	3年-20°C粉狀	儲備液保存和期限建議分裝儲備液，避免反復(fù)凍融！	1年-80°C溶于溶劑
儲存條件(自收到貨起)	3年-20°C粉狀	儲備液保存和期限建議分裝儲備液，避免反復(fù)凍融！	1個(gè)月-20°C溶于溶劑

體外溶解度
批次：

DMSO : 49 mg/mL ( (199.03 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : 49 mg/mL (199.03 mM)

Ethanol : 10 mg/mL (40.61 mM)

DMSO : 49 mg/mL ( (199.03 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : 49 mg/mL (199.03 mM)

Ethanol : 25 mg/mL (101.54 mM)

DMSO : 49 mg/mL ( (199.03 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : 49 mg/mL (199.03 mM)

Ethanol : 10 mg/mL (40.61 mM)

DMSO : 49 mg/mL ( (199.03 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO)

Water : 49 mg/mL (199.03 mM)

Ethanol : 12 mg/mL (48.74 mM)

摩爾濃度計(jì)算器

體內(nèi)溶解配方批次：現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑				動(dòng)物體內(nèi)配方計(jì)算器
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
澄清溶液	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O 該配方已經(jīng)過Selleck實(shí)驗(yàn)室實(shí)測。如果上述溶解方案不能滿足您的需求，可聯(lián)系Selleck銷售提供定制化測試。	3.650mg/ml (14.83mM)	以 1 mL 工作液為例,取50μL73mg/ml的澄清DMSO儲備液加到400μLPEG300中,混合均勻使其澄清;向上述體系中加入50μLTween80,混合均勻使其澄清;然后繼續(xù)加入500μLddH2O定容至1mL。工作液請現(xiàn)配現(xiàn)用!
澄清溶液	5% DMSO 1 95% Corn oil 該配方已經(jīng)過Selleck實(shí)驗(yàn)室實(shí)測。如果上述溶解方案不能滿足您的需求，可聯(lián)系Selleck銷售提供定制化測試。	0.456mg/ml (1.85mM)	以1 mL工作液為例，取50μL 9.12mg/ml的澄清DMSO儲備液加到950μL玉米油中，混合均勻。工作液請現(xiàn)配現(xiàn)用！

實(shí)驗(yàn)計(jì)算

摩爾濃度計(jì)算器

質(zhì)量	濃度	體積	分子量
=	×	×

稀釋計(jì)算器分子量計(jì)算器

動(dòng)物體內(nèi)配方計(jì)算器（澄清溶液）

第一步：請輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過程中的損耗，建議多配一只動(dòng)物的藥量）

給藥劑量 mg/kg 動(dòng)物平均體重 g 每只動(dòng)物給藥體積 μL 動(dòng)物數(shù)量只

第二步：請輸入動(dòng)物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

計(jì)算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH₂O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購、運(yùn)輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱[email protected]，直接聯(lián)系到我們。我們會在24小時(shí)內(nèi)盡快聯(lián)系您。

操作手冊

如果有其他問題，請給我們留言。

* 必填項(xiàng)

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Floxuridine (FUDR)

產(chǎn)品質(zhì)控

Floxuridine (FUDR)相關(guān)產(chǎn)品

相關(guān)信號通路圖

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

生物活性

化學(xué)信息&溶解度

實(shí)驗(yàn)計(jì)算

技術(shù)支持